Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Nursing Open|February 23, 2023
Health-related experiences of adults with chronic cough: Empirical research mixed methodsMichael Weiner, Jessica Weaver, Tayler Gowan, et al.Journal of Clinical Medicine|October 14, 2023
Patterns of Cough Medication Prescribing among Patients with Chronic Cough in Florida: 2012-2021Seonkyeong Yang, Shu Huang, Juan M Hincapie-Castillo, et al.Journal of Medical Virology|August 27, 2019
Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipientsLynn El Haddad, Shashank S Ghantoji, Anne K Park, et al.Journal of Clinical Medicine|July 9, 2022
Evaluation of Cough Medication Use Patterns in Ambulatory Care Settings in the United States: 2003-2018Seonkyeong Yang, Juan M Hincapie-Castillo, Xuehua Ke, et al.Lung|March 6, 2023
The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic CoughLorcan McGarvey, Mandel Sher, Yury Grigorievich Shvarts, et al.Lung|April 7, 2021
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist GefapixantAlyn H Morice, Surinder S Birring, Jaclyn A Smith, et al.The Journal of Allergy and Clinical Immunology. in Practice|August 1, 2021
Prevalence and Burden of Chronic Cough in the United StatesEli O Meltzer, Robert S Zeiger, Peter Dicpinigaitis, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 15, 2022
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic coughPeter V Dicpinigaitis, Surinder S Birring, Michael Blaiss, et al.Lung|July 27, 2022
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined SubgroupsJaclyn A Smith, Surinder S Birring, Peter V Dicpinigaitis, et al.Lancet (London, England)|March 6, 2022
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsLorcan P McGarvey, Surinder S Birring, Alyn H Morice, et al.Pageof 4